

NET IMPACT

Thrivership & Research Education Program












**Saturday, September 13, 2025
3:00 p.m.**

University of Alabama at Birmingham
National Alumni Society House
1301 10th Ave. South
Birmingham, AL 35294



TABLE OF CONTENTS

Scroll or click on the text or logos below to navigate to sections of the booklet.
To return to the Table of Contents, click the round, red TOC button at the end of
each section. For optimal interactive performance, view this document in "read" mode.

	Welcome	2
	Agenda.....	3
	Fast Facts About NETs.....	4
	About NETRF	5
	Get to Know Our Speakers	7
	NET Knowledge Center.....	10
	NETWise	11
	Know Your NETs	12
	Clinical Trials	13
	Breakthroughs Today, Cures Tomorrow	14
	A Word of Thanks.....	16



WELCOME

Welcome to NET Impact, NETRF's Thrivership and Research Patient Education Program. We are excited to be with you in Birmingham.

Our focus today is two-fold—what's new in neuroendocrine cancer research and treatment, plus how to thrive and live well with NETs. Thank you to our physician co-chairs, Drs. Dan Halperin and Bart Rose, for their participation and guidance. We thank all our speakers for sharing their expertise with you.

We hope you will increase your knowledge about neuroendocrine cancer today and gain some strategies to manage the challenges that accompany a neuroendocrine cancer diagnosis. The conference is also an opportunity to meet fellow patients and caregivers and network with others who can understand your experience.

NETRF sincerely thanks our sponsors, Exelixis, ITM, Curium, Crinetics, Novartis, and Lantheum, who help make this conference possible, and we extend our gratitude to NANETS for their collaboration.

Above all, know that you are not alone if you have neuroendocrine cancer. NETRF is here as a resource today and every day. We welcome your feedback about this conference and how we can best meet your educational needs. Thank you for your time and interest!



Elyse Gellerman, MHS
*Chief Executive Officer,
Neuroendocrine Tumor Research Foundation*

Note to Attendees

This patient and caregiver education conference is not intended as and shall not be relied upon as medical advice. The Neuroendocrine Tumor Research Foundation encourages all users to discuss any information found here with their oncologist, physician, or appropriate qualified health professional. Attending this conference does not constitute a patient-physician relationship. The Neuroendocrine Tumor Research Foundation does not represent that any information provided here should supplant the reasoned, informed advice of a patient's oncologist, physician, or appropriate qualified health professional.

September 13, 2025, 3:00 p.m.

University of Alabama at Birmingham, National Alumni Society House
1301 10th Avenue South, Birmingham, Alabama

AGENDA

- 3:00 p.m. Thrivership Meet and Greet**
Refreshments will be provided.
- 4:20 p.m. Welcome and Program Introduction**
Elyse Gellerman, MHS – Chief Executive Officer, NETRF
- 4:30 p.m. What Do We Know Now?**
Simron Singh, MD, MPH, FRCPC – Sunnybrook Odette Cancer Centre
- 4:45 p.m. What's New in Nuclear Medicine and PRRT**
Saima Muzahair, MD, FCPS, FRCPE – Emory University
- 5:00 p.m. What's New in Clinical Trials?**
Udhayvir S. Grewal, MD – Emory University
- 5:15 p.m. The Role of Multidisciplinary Clinics in Neuroendocrine Cancer and Metastatic Disease Care**
Daniel M. Halperin, MD – Emory University
Bart Rose, III, MD, MAS – University of Alabama at Birmingham
- 5:30 p.m. The Future of Basic and Translational Research**
Anna Greene, PhD – Director of Research, NETRF
- 5:50 p.m. NET Thrivership: Strengthening Mental Health and Managing Stress**
Jessica Thomas, LCSW – Director of Patient Education, NETRF
- 6:10 p.m. NET IMPACT Program Q&A Panel**
Panelists: Dan Halperin, MD; Simron Singh, MD, MPH, FRCPC;
Bart Rose, III, MD, MAS; Udhay Grewal, MD; Anna Greene, PhD;
Saima Muzahair, MD, FCPS, FRCPE
- 7:05 p.m. Program Closure and Evaluation**
Elyse Gellerman, MHS – Chief Executive Officer, NETRF



Sponsors:





Fast Facts About NETs

- Neuroendocrine cancer is an uncommon cancer yet the incidence has been increasing in recent decades. This is attributed in part to improvements in diagnostic techniques and greater awareness.
- More than **12,000 people** in the U.S. are diagnosed with a neuroendocrine cancer each year.
- The average length of time from first symptoms to diagnosis is **4.3 years**.¹
- The average number of health care visits made before a neuroendocrine cancer diagnosis is **11.8 visits**.¹
- Up to **58% of patients** had metastases at diagnosis.

¹ Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;3(1):43-53.

ABOUT THE NEUROENDOCRINE TUMOR RESEARCH FOUNDATION (NETRF)

The Neuroendocrine Tumor Research Foundation is the largest global funder of neuroendocrine cancer research, investing \$40 million in landmark research since 2005. NETRF's mission is to drive transformational discoveries in the study of neuroendocrine tumors. We are leading the fight to bring life-changing treatments to families and to find a cure.



NETRF:

- Invests boldly in the most promising scientific projects worldwide
- Funds and nurtures the most brilliant NET scientists who bring their original thinking and determined spirit to their work
- Offers hope to patients and families
- Shapes the future of neuroendocrine cancer care to save lives

NETRF's impact on the field of neuroendocrine cancer research has been profound. Thanks to NETRF-funded discoveries and the efforts of the neuroendocrine cancer medical community, the therapeutic landscape of neuroendocrine cancer management looks entirely different now than it did in 2005, when NETRF began. Such advances are not random. They are the direct result of many years of NETRF-funded research.

\$40M in NETRF funded breakthrough science

22 clinical trials fueled by NETRF-supported research



156

research projects funded



76

institutions in 17 countries



7

new therapies since NETRF began



View our 2024 Annual Report to see the impact we have had and a timeline commemorating 20 years of driving breakthroughs.

EDUCATING AND EMPOWERING PATIENTS

NETRF is dedicated to the thousands of patients, families, and caregivers affected by neuroendocrine cancer. We provide expert educational resources to help you understand your diagnosis, make informed health care decisions, and thrive.

Our resources include:



NET Knowledge Center

A comprehensive online resource for information, engagement, and community building



Neuroendocrine Cancer Guide

A hands-on reference for the tests, treatments, and management of neuroendocrine cancer



NETWise Podcast series

Insights and perspectives on living with neuroendocrine cancer



NETRF YouTube library

Videos about diagnosis, treatment, research, and living with neuroendocrine cancer



Patient and caregiver education conferences

In-person and virtual events for knowledge- and community-building



Searchable databases

Includes neuroendocrine cancer doctors and multidisciplinary treatment programs

GET TO KNOW OUR SPEAKERS



Elyse Gellerman, MHS

Chief Executive Officer, NETRF

Elyse has been Chief Executive Officer of the Neuroendocrine Tumor Research Foundation since November 2017. As CEO, she has built a team that has vastly expanded NETRF's global reach in research funding and patient education. Prior to NETRF, Elyse was a Regional Vice President for Sarah Cannon, the oncology service line for Hospital Corporation of America (HCA). Elyse spent more than 20 years in hospital service line development, operations consulting, and marketing. She has served on the national board at Susan B. Komen, and been a member of other health-related nonprofit boards. In 2011, Elyse was recognized by the Obama Administration as a Champion for Change in the fight against breast cancer. Elyse graduated from Cornell University and has a master's degree in healthcare systems from the University of Denver.



Anna Greene, PhD

Director of Research, NETRF

As NETRF's Director of Research, Dr. Greene leads the foundation's research programs, oversees the annual grant cycle, supervises post-award processes, organizes the annual research symposium, and reports research impact and outcomes to the community. She is motivated to help advance neuroendocrine cancer research to understand the disease better and ultimately identify better treatments and cures. She earned a BS in chemistry from Berry College and a PhD in chemistry from Dartmouth College.



Udhayvir S. Grewal, MD

Emory University

Dr. Grewal is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. He completed his internal medicine residency at LSU Health Sciences Center-Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he remains an active collaborator with the UIowa NET SPORE team.

GET TO KNOW OUR SPEAKERS, cont.



Daniel M. Halperin, MD

Emory University

A board-certified medical oncologist, Daniel M. Halperin, MD, specializes in the treatment of neuroendocrine cancer. Dr. Halperin is part of the gastrointestinal oncology team at Winship Cancer Institute of Emory University. He is an associate professor and serves as vice chair for clinical affairs in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Halperin is a member of NETRF's Board of Scientific Advisors and also serves on the NANETS Board of Directors.

He received his medical degree from Weill Cornell Medical College in New York City, New York. Dr. Halperin completed his internal medicine residency at Brigham and Women's Hospital in Boston, Massachusetts and his medical oncology training at University of Texas MD Anderson Cancer Center in Houston, Texas.



Saima Muzahair, MD, FCPS, FRCPE

Emory University

Dr. Muzahir is associate professor of radiology, serving as Enterprise Theranostics lead in the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University Hospital, Atlanta Georgia. Dr. Muzahir is the Associate Program Director for Emory Molecular Imaging and Therapy (MIT) fellowship. She is the program manager for RAD-AID Pakistan and is currently serving as the vice president for Pakistan Society of Nuclear Medicine (PSNM). Dr. Muzahir received her medical degree from Nishtar Medical College Pakistan and completed a four-year residency in Nuclear Medicine at Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore Pakistan. After completing her training in Pakistan, she moved to the United States and did her residency in Nuclear Medicine at the University of Iowa Hospitals and Clinics, Iowa City, followed by a PET-CT fellowship from University of Wisconsin Madison. Dr. Muzahir serves on the Board of Directors for SNMMI General Clinical Nuclear Medicine Council and also serves as a Director for the American Board of Nuclear Medicine. Dr. Muzahir's research interests include radioligand therapies and oncologic PET-CT imaging.

GET TO KNOW OUR SPEAKERS, cont.



Bart Rose, III, MD, MAS

University of Alabama at Birmingham

Dr. J. Bart Rose joined the faculty of the UAB Department of Surgery Division of Surgical Oncology in 2017. He has a combined research and clinical appointment. He has been engaged in scientific research for over 20 years. His focus since entering the field of surgery has been on biomarker research and mechanisms of cancer development in liver, pancreas, and bile duct cancers (specifically neuroendocrine tumors). He has presented on novel uses of established biomarkers in pancreatic cancer, was the first to report on the clinical utility of a bile-based biomarker in patients with bile duct cancer (cholangiocarcinoma), and is currently investigating new ways to treat tumors of the pancreas and GI tract. Dr. Rose has been a recipient of the NETRF/NANETS Basic Translational Science Investigator (BTSI) award.



Simron Singh, MD, MPH, FRCPC

Sunnybrook Odette Cancer Centre

Dr. Simron Singh is a medical oncologist and affiliate scientist in the Odette Cancer Research Program at Sunnybrook Research Institute. He is the co-founder of the Susan Leslie Clinic for Neuroendocrine Cancers at the Odette Cancer Centre Sunnybrook Health Sciences Centre. He is also an assistant professor at the University of Toronto. He completed his B.Sc. and MD at the University of Alberta in Edmonton. He completed postgraduate training in internal medicine at Queen's University in Kingston and medical oncology at the University of Toronto. After completing his clinical training, Dr. Singh received his master's degree in public health from Harvard University.



Jessica Thomas, LCSW

Director of Patient Education, NETRF

Jessica Thomas, LCSW, is a clinical social worker with nearly 20 years of experience supporting patients and caregivers navigating neurology, oncology, and chronic illness. With a career rooted in mental health care for those facing complex medical conditions, Jessica is deeply committed to helping individuals and families identify and embrace what matters most to them while living with chronic, progressive, or terminal illness. She is passionate about fostering community, advancing patient-centered care, supporting research, and improving the overall patient experience and outcomes.



BECOME INFORMED, ENGAGED AND CONNECTED IN YOUR NET JOURNEY

Current and accurate patient education and information is vital to helping you live well with neuroendocrine cancer. We know that finding credible information and education can be challenging and difficult to navigate.

NETRF's NET Knowledge Center is a comprehensive resource organized to direct you to the information you need to be engaged in your neuroendocrine cancer journey while connecting you to a community of resources.

INFORMATION

Learn more about neuroendocrine cancers

A diagnosis of a neuroendocrine tumor often comes with many questions and concerns. These resources explain the various types of neuroendocrine cancers, diagnostic tests, and risks so you and your family can better understand your condition.

ENGAGEMENT

Take the next step regarding your diagnosis

With many different kinds of neuroendocrine cancers, it's important to find the best possible care and treatment. These resources explore finding specialists, treatments, and how best to care for yourself.

COMMUNITY

Connect with more people and resources about neuroendocrine cancer

When it comes to neuroendocrine tumors, it takes a community. Explore the many ways you can access the latest information on treatments and research progress, and what's happening in the neuroendocrine cancer community.



Visit the NET Knowledge Center at
netrf.org/for-patients/ or scan this QR code.



NETwise

A Podcast About Neuroendocrine Cancer

Being diagnosed with neuroendocrine cancer, an uncommon disease, can feel isolating and overwhelming. The NETWise podcast is here to help patients and caregivers navigate the world of neuroendocrine tumors and carcinomas.


Listen as the NET Research Foundation (NETRF) speaks with experts and patients who will help you to understand diagnosis, treatment, thrivership and everything in between. NETWise is for everyone, from newly diagnosed patients to longtime survivors, as well as caregivers and family members.

This is your guide to learning, listening, knowing, and being NETWise.

Check out these episodes for more on what you have heard during KNOW YOUR NETs:

- [Care for the Neuroendocrine Carcinoma Caregiver](#)
- [Understanding Neuroendocrine Carcinoma](#)
- [Managing the Financial Burden of Neuroendocrine Cancer](#)
- [Radiopharmaceutical Treatment: FAQs and Insights](#)
- [How Could AI Change Neuroendocrine Cancer](#)
- [Finding Happiness While Living With Neuroendocrine Cancer](#)
- [Managing Symptoms of NENs](#)

Subscribe [here](#) and find our entire NETWise library. Listen to NETWise wherever you get your podcasts.



Neuroendocrine Tumor
Research Foundation
100 Hancock Street, Third Floor
Quincy, MA 02171
(617) 946-1780 | netrf.org



From our 2025 Know Your NETs Conference

NETs and NECs 101

Presented by Kimberly Perez, MD, Dana Farber Cancer Institute



Know Your NETs Presentation:



The 2025 Know Your NETs Preconference Video: NETs and NECs 101



Kimberly Perez, MD
Dana-Farber Cancer Institute

This introductory session is designed to help patients, caregivers, and advocates understand the basics of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Dr. Perez breaks down the essential concepts, terminology, and differences between NETs and NECs in a clear and approachable way — equipping you with the knowledge to get the most out of the full conference. Topics include:

- What are NETs and NECs?
- Key differences in biology and behavior
- How NETs and NECs are diagnosed and staged
- An overview of treatment options and care teams

Whether you're newly diagnosed or looking for a refresher, this video ensures you're prepared to take charge of your care.




Explore the full Know Your NETs 2025
playlist on our Youtube channel:
youtube.com/@NETRF or scan the QR code

CLINICAL TRIALS

Clinical trials can provide patients with innovative treatments and are the final step in a long process that begins with research in a lab. Before any new treatment is used in people in clinical trials, researchers work for many years in the lab to understand its effects by testing it first on cells or in animals. They then work to determine the best dose for treatment, the side effects the drug may cause, and how the effectiveness of the drug compares to current treatments. It can take 10-15 years to develop a new drug to the point of a first clinical trial. Our online NET Trial Finder can connect you to clinical trials in your area.

NET Trial Finder



The screenshot shows the NET Trial Finder website. At the top, there is a navigation bar with the NET logo, the text "NEUROENDOCRINE TUMOR RESEARCH FOUNDATION", a small "powered by" logo for "Ancora.ai", and links for "LEARN", "LOGIN", and "SIGN UP". Below the navigation bar, the main heading is "MATCH & CONNECT" followed by "Finding clinical trials made simple". A subtext states: "Clinical trials can provide patients with innovative treatments. Ancora.ai helps find your personalized trial options. It's easy, fast, and free." To the right of the text is an illustration of a stethoscope, a computer monitor displaying a checklist, and a pill bottle. Below this is a search bar with a dropdown menu set to "Neuroendocrine tumors/cancer", a text input field for "Enter city and country", and a "Find Trials" button. At the bottom, there is a section titled "Explore trials by category" with a button for "Radiopharmaceuticals" and a right arrow.



FIND A CLINICAL TRIAL

There are many clinical trials for neuroendocrine cancer. Scan this QR code to access the NET Trial Finder, or visit netrf.org/for-patients/trial-finder/

Find it early. Treat it better. Cure it faster.



“I truly believe in the mission and the great work that NETRF is doing year in and year out. I want to be part of the solution — and I want to see a future where we find a cure.”

— Steve Kaufer,
NETRF Board Member,
Co-Founder, TripAdvisor,
Co-Founder, Give Freely

For 20 years, NETRF has led the global charge to transform neuroendocrine cancer treatment.

Now, we are launching our most ambitious campaign yet — a **\$25 million** effort to accelerate the bold science that will deliver new therapies and, ultimately, cures.

With your support, NETRF is advancing progress in three urgent and high-impact areas:

- **Early Detection** — So patients are diagnosed sooner, when treatment is more effective
- **New Therapeutic Development** — To expand treatment options and improve survival
- **Personalized Treatments** — To ensure every patient receives the right care at the right time

**Researchers are ready. Bold ideas are waiting.
They just need our support.**

Your Impact So Far:



156

research projects
funded



76

institutions in
17 countries



70%

increase in research
proposals since 2023

\$40 million

invested in breakthrough science

22

clinical trials fueled by
NETRF-supported research



Early Detection



CURES



This Is the Moment to Create Tomorrow's Cures

The discoveries happening today — in labs, clinics, and collaborative research teams — are transforming what's possible for patients and families facing neuroendocrine cancer.

But breakthroughs need you.

Your gift drives progress by:

- Funding life-changing research led by the world's leading scientists
- Powering innovations like CAR T-cell therapy from lab to lives
- Equipping patients and caregivers with trusted education and resources

As we mark 20 years of progress, let's celebrate by doubling down on our mission.

Make your gift today! Visit netrf.org/breakthroughs or scan the QR code to learn more.




**Breakthroughs Today, Cures Tomorrow.
Our future starts now.**



Robust Researcher Pipeline



Innovative Treatments



Precision Medicine

«
TOC

A WORD OF THANKS!

Thank you for taking part in NETRF's NET Impact conference. We hope you found the sessions informative and valuable.

If you have any questions about NETRF, our research and resources, and how we can best support you on your journey with neuroendocrine cancer, please contact us at info@netrf.org.

We are grateful to our generous partners and friends like you. Thanks to your support, NETRF can host educational conferences and advance research, opening new doors to neuroendocrine cancer discoveries.

NETRF greatly appreciates the generosity of the following sponsors who made this educational program possible. Thank you!

Our Sponsors



**NEUROENDOCRINE TUMOR
RESEARCH FOUNDATION**
DEDICATED TO CURING NEUROENDOCRINE CANCER

Visit our YOUTUBE channel for patient education videos.



Connect with us and other patients, caregivers, and family members online:

